FDA Approves BAXFENDY (BAXDROSTAT) — New Treatment Available
WHY IT MATTERS
This is the first FDA approval of baxdrostat, but the specific rare disease indication is not detailed in this announcement — patients should check with their doctor or the FDA's full label to confirm if this drug applies to their condition.
The FDA has approved a new drug called BAXFENDY (generic name: baxdrostat) made by AstraZeneca. This approval means the drug is now available for patients to use. The approval was granted on May 15, 2026, after the drug met safety and effectiveness standards.
Drug: BAXFENDY Generic name: BAXDROSTAT Sponsor: ASTRAZENECA PHARMS Application: NDA219878 (ORIG) FDA approval date: 2026-05-15 Source: FDA Drugs@FDA database
ASK YOUR DOCTOR
Ask your doctor whether BAXFENDY might be appropriate for your condition and whether you meet the eligibility criteria for treatment.